A detailed history of Exchange Traded Concepts, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Exchange Traded Concepts, LLC holds 47,391 shares of PTGX stock, worth $2.36 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
47,391
Previous 27,392 73.01%
Holding current value
$2.36 Million
Previous $1.32 Million 97.81%
% of portfolio
0.03%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 10, 2025

BUY
$40.89 - $56.37 $817,759 - $1.13 Million
19,999 Added 73.01%
47,391 $2.62 Million
Q1 2025

Apr 17, 2025

BUY
$35.09 - $59.76 $925,218 - $1.58 Million
26,367 Added 2572.39%
27,392 $1.32 Million
Q4 2024

Jan 21, 2025

BUY
$38.51 - $48.43 $2,464 - $3,099
64 Added 6.66%
1,025 $39,000
Q3 2024

Oct 10, 2024

BUY
$33.72 - $47.33 $32,404 - $45,484
961 New
961 $43,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.45B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Exchange Traded Concepts, LLC Portfolio

Follow Exchange Traded Concepts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exchange Traded Concepts, LLC with notifications on news.